Expert Interviews

An expert dermatologist outlines factors that influence treatment selection for patients with atopic dermatitis and discusses how often patients need systemic therapy, given the available topical therapy options.

Veteran healthcare lobbyist discussed the prospects for the Senate passing comprehensive PBM legislation in the most recent episode of Managed Healthcare's DC Roundtable podcast.

A diabetes expert investigates how comorbidities like obesity, hypertension, hyperlipidemia, and depression impede effective diabetes management, while concurrently exploring potential health plan benefits that could synergistically address these coexisting conditions to improve overall care.

David Hines examines the profound impact of social determinants like food insecurity, housing instability, and limited access to healthcare services on the health outcomes of individuals with diabetes, while also delving into the multifaceted barriers hindering effective diabetes management and offering insights to overcome these challenges.

Gabriela Hobbs, MD, and Timothy Mok, PharmD, BCPS, BCOP, close the discussion with key takeaways for payers to consider related to ruxolitinib and insights on future research.

A KOL considers how health care providers can enhance patient understanding of Demodex blepharitis and issues surrounding treatment adherence.

Dr Eichenfield provides a comprehensive overview of topical and systemic treatments available for the treatment of patients with atopic dermatitis.

Lawrence Eichenfield, MD, discusses how the treatment landscape for atopic dermatitis has changed in recent years and provides clinical insights on the clinical burden and most burdensome symptoms of the disease.

Selina McGee, OD, FAAO, evaluates the cost and efficacy of in-office procedures like microblepharoexfoliation, the potential clinical and economic costs associated with delaying access to the FDA-approved treatment through prior authorization or mandating prior use of traditional over-the-counter therapies like tea tree oil and lid wipes, and considers impact on patient adherence.

Following a review of the safety analysis of MAJIC-PV, the panel discusses the main limitations and key takeaways from the study.

A comprehensive overview of key findings from the MAJIC-PV trial investigating ruxolitinib in patients with polycythemia vera, highlighting efficacy and symptom improvement.

A key opinion leader examines the historical context of Demodex blepharitis treatment, discussing the efficacy and limitations of previous therapies, and emphasizes a recently FDA-approved therapy that directly targets Demodex mites, leading to improved efficacy compared to treatments that only address symptoms.

Gabriela Hobbs, MD, describes characteristics of the patient population included in the MAJIC-PV study, and analyzes best available therapies received in the comparator arm.

Experts on polycythemia vera provide a comprehensive overview of the objectives and study design of the MAJIC-PV clinical trial, highlighting key endpoints.

Selina McGee, OD, FAAO, examines the prevalence, primary symptoms, quality of life impact, and the issues of underdiagnosis and misdiagnosis surrounding Demodex blepharitis in the United States.

Gabriela Hobbs, MD, provides an overview of the role of ruxolitinib in treating patients with hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera.

Timothy Mok, PharmD, BCPS, BCOP, and Gabriela Hobbs, MD, introduce themselves and provide insights on the prevalence of hydroxyurea resistance or intolerance in patients with polycythemia vera (PV) and how it impacts treatment decisions and costs.

Mahsa Salsabili, PharmD, PhD, explores risk and value-based contracting for prescription digital therapeutics, along with strategies for manufacturers to support their utilization and optimization, while also delving into cost-effectiveness modeling and budget impact analysis.

Mahsa Salsabili, PharmD, PhD, offers a comprehensive list of factors for healthcare providers and payers to consider in order to streamline the process of prescription digital therapeutics to patients.

Physician shortages and retail pharmacy closures are creating areas without access to healthcare in rural regions and inner cities, warns Luke Greenwalt, vice president, market access, at IQVIA.

Newly launched drugs coming are facing payer controls and other hurdles, says Luke Greenwalt, vice president, market access, at IQVIA.

Mahsa Salsabili, PharmD, PhD, addresses the challenges surrounding insurance approval and the limited announcements regarding coverage for prescription digital therapeutics, while exploring various reimbursement models, such as value-based contracts and outcome-based rebates.

Mahsa Salsabili, PharmD, PhD, delves into the FDA approval process for prescription digital therapeutics , which requires market approval, clinical studies and real-world evidence, to establish their efficacy in treating the targeted disease or condition.

Leaders at UC Davis Health created an emerging therapies committee to review and prepare for the wave of treatments that cost millions of dollars.